Ononis Repens Whole

Dosage for Ononis Repens Whole is highly individualized and must be determined by an allergy specialist. There is no 'standard' dose because patients vary significantly in their level of sensitivity.

Diagnostic Testing

• Percutaneous (Prick) Testing: Usually performed using a 1:10 or 1:20 w/v concentration. A single drop is applied to the skin, and a sterile lancet is used to prick the epidermis.
• Intradermal Testing: If the prick test is negative, an intradermal injection of 0.02 to 0.05 mL of a much more dilute solution (e.g., 1:1000 or 1:500 w/v) may be administered.

Immunotherapy (SCIT)

• Build-up Phase: Starts with a very low dose (e.g., 0.05 mL of a 1:100,000 w/v dilution). Injections are typically given 1-2 times per week, with the dose increasing by 25% to 100% at each visit, provided no significant reactions occur.
• Maintenance Phase: Once the 'maintenance dose' is reached (the highest dose tolerated by the patient that provides symptomatic relief), the interval between injections is increased to every 2-4 weeks.

Ononis Repens Whole is generally considered safe for use in children, though testing is rarely performed on infants under the age of two. Pediatric dosing follows the same weight/volume titration principles as adult dosing. However, the clinician must exercise extreme caution as children may have difficulty communicating the early symptoms of a systemic reaction.

Renal Impairment

No specific dose adjustments are required for renal impairment, as the proteins are not primarily cleared by the kidneys. However, the patient's overall health must be stable.

Hepatic Impairment

No dosage adjustments are defined for hepatic impairment.

Elderly Patients

Older adults may have a reduced skin wheal response, potentially leading to false-negative diagnostic tests. Furthermore, the risk of cardiovascular complications during a systemic reaction (anaphylaxis) is higher in the elderly, necessitating lower starting doses and slower titration.

Ononis Repens Whole must NEVER be self-administered. It must be administered by a healthcare professional in a clinical setting equipped to handle anaphylaxis.

• Administration Site: Subcutaneous injection in the posterior aspect of the upper arm.
• Observation: The patient must remain in the clinic for at least 30 minutes following any injection to monitor for signs of a systemic reaction.
• Storage: Store the extract in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Discard if the solution becomes turbid or changes color significantly.

In immunotherapy, if a dose is missed:

• Short Delay (1-7 days): The previous dose may be repeated.
• Long Delay (over 2 weeks): The dose may need to be reduced significantly to prevent a reaction due to a loss of tolerance.
• Extended Delay: The build-up phase may need to be restarted from the beginning.

An 'overdose' in this context usually refers to an injection of a concentration higher than the patient's current tolerance level.

• Signs: Rapid onset of hives, swelling of the throat, wheezing, hypotension (low blood pressure), and loss of consciousness.
• Emergency Measures: Immediate administration of Epinephrine (1:1000) intramuscularly, followed by oxygen, IV fluids, and antihistamines. The patient should be transported to an emergency department immediately.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance.

Most patients receiving Ononis Repens Whole will experience local reactions at the site of injection or testing. These are generally considered part of the expected response.

• Local Wheal and Flare: A raised, itchy bump (wheal) surrounded by redness (flare). This typically appears within 15-20 minutes and resolves within a few hours.
• Local Swelling: Swelling at the injection site that may be 1-5 cm in diameter. This can feel warm or slightly tender.
• Pruritus (Itching): Intense itching at the site of administration.

• Large Local Reactions (LLR): Swelling that exceeds 5-10 cm in diameter or extends past the nearest joint. These may last for 24-48 hours.
• Fatigue: Some patients report feeling unusually tired for several hours after an immunotherapy injection.
• Headache: Mild to moderate headache following administration.
• Nasal Congestion: A temporary increase in hay fever symptoms shortly after the injection.

• Urticaria (Hives): Generalized hives appearing on areas of the body distant from the injection site.
• Angioedema: Swelling of the deeper layers of the skin, often around the eyes or lips.
• Lymphadenopathy: Temporary swelling of the lymph nodes near the injection site.

Serious side effects are almost always related to systemic hypersensitivity (anaphylaxis). These require immediate intervention.

• Respiratory Distress: Wheezing, chest tightness, shortness of breath, or a persistent cough. This indicates the allergen is causing bronchospasm.
• Laryngeal Edema: A 'lump in the throat,' hoarseness, or difficulty swallowing, indicating airway swelling.
• Hypotension: A sudden drop in blood pressure, which may manifest as dizziness, fainting, or 'seeing stars.'
• Gastrointestinal Distress: Severe abdominal cramping, vomiting, or diarrhea occurring shortly after the injection.
• Cyanosis: Bluish tint to the lips or fingernails, indicating poor oxygenation.

> Warning: Stop taking Ononis Repens Whole and call your doctor immediately if you experience any of these symptoms. These reactions can be life-threatening if not treated within minutes.

There are no known long-term 'toxic' effects of Ononis Repens Whole on organs like the liver or kidneys. The primary long-term risk is the development of new sensitivities or the exacerbation of asthma if the immunotherapy is not managed correctly. Some patients may develop 'serum sickness' (fever, joint pain, rash) if they receive excessively high doses of foreign proteins over a long period, though this is extremely rare with modern extracts.

WARNING: RISK OF ANAPHYLAXIS

• Ononis Repens Whole allergenic extract can cause severe, life-threatening systemic reactions, including anaphylaxis.
• This product should only be administered by healthcare professionals trained in the management of anaphylaxis and in a facility equipped with emergency supplies (epinephrine, oxygen, airway management tools).
• Patients with unstable or severe asthma are at a higher risk for fatal reactions.
• Patients taking beta-blockers may be resistant to the effects of epinephrine used during an emergency.
• Always observe the patient for at least 30 minutes after administration.

Report any unusual symptoms to your healthcare provider.

Ononis Repens Whole is a potent biological product. Its safety depends entirely on correct administration and patient selection. Patients must be aware that while the goal is to reduce allergy symptoms, the treatment itself involves injecting the very substance they are allergic to, which carries inherent risks.

No FDA black box warnings are specifically unique to Ononis Repens Whole beyond the standard class warning for all allergenic extracts. The standard warning emphasizes that these products can cause severe systemic reactions (anaphylaxis), must be administered by specialists, and require a 30-minute post-injection observation period. Fatalities have occurred with allergenic extracts when these protocols were not followed.

• Allergic Reactions / Anaphylaxis Risk: This is the primary concern. Risk factors include high levels of sensitivity, a high dose of allergen, and administration during the peak pollen season for Restharrow.
• Asthma Status: Patients must have their asthma under control before receiving an injection. If a patient is experiencing an asthma flare-up or has a peak flow reading significantly below their personal best, the injection must be deferred.
• Acute Illness: Injections should be postponed if the patient has a fever or a significant respiratory infection.
• Skin Condition: For diagnostic testing, the skin at the test site must be free of active dermatitis or eczema to ensure accurate results.

• Observation Period: A strict 30-minute wait time in the clinic after every injection.
• Peak Flow Monitoring: For asthmatic patients, clinicians may require a peak flow measurement before and after the injection.
• Symptom Diary: Patients are often asked to keep a diary of any 'late-phase' reactions (swelling that occurs 6-12 hours after the injection).

Ononis Repens Whole does not typically cause sedation. However, if a patient experiences a systemic reaction or receives epinephrine to treat a reaction, they should not drive or operate machinery until they have fully recovered and been cleared by a physician.

Alcohol consumption should be avoided on the day of an immunotherapy injection. Alcohol can increase peripheral vasodilation, which may potentially accelerate the absorption of the allergen or exacerbate the severity of an allergic reaction.

If a patient experiences a severe systemic reaction, the healthcare provider will re-evaluate the risks and benefits of continuing therapy. In many cases, the dose is significantly reduced, or the therapy is discontinued entirely. There is no 'withdrawal syndrome' associated with stopping allergenic extracts, but the patient's allergy symptoms will likely return to their baseline levels over time.

> Important: Discuss all your medical conditions with your healthcare provider before starting Ononis Repens Whole.

• Beta-Blockers (e.g., Propranolol, Metoprolol): These medications are contraindicated in many patients receiving immunotherapy. Beta-blockers can make an allergic reaction more severe and, more importantly, they can block the life-saving effects of epinephrine (adrenaline) used to treat anaphylaxis.

• ACE Inhibitors (e.g., Lisinopril): Some studies suggest that ACE inhibitors may increase the risk of severe systemic reactions or interfere with the body's compensatory mechanisms during anaphylaxis.
• MAOIs and Tricyclic Antidepressants: These drugs can potentiate the effects of epinephrine, leading to dangerous spikes in blood pressure if epinephrine must be administered for a reaction.

• Antihistamines (H1-blockers like Cetirizine, Loratadine): These do not cause a safety risk but will cause a 'false negative' on diagnostic skin tests. They must be discontinued for 3-7 days prior to testing.
• H2-blockers (e.g., Famotidine): These can also suppress the skin's response to allergen testing and should be discontinued 48 hours prior to testing.
• Topical Steroids: Applying steroids to the skin at the site of testing can suppress the wheal and flare reaction.

There are no direct food interactions with Ononis Repens Whole. However, patients with a 'pollen-food allergy syndrome' (Oral Allergy Syndrome) may experience cross-reactivity. If a patient is highly sensitive to Restharrow, they may also experience mild itching in the mouth when eating related legumes, though this is clinically distinct from the injection process.

• St. John's Wort: May theoretically affect the metabolism of medications used to treat anaphylaxis, though the clinical significance is low.
• Astragalus: As an immune-modulating herb, it could theoretically interfere with the desensitization goals of immunotherapy.

• Skin Prick Tests: As mentioned, antihistamines and certain antidepressants will interfere with the results.
• Serum IgE Tests (RAST/ImmunoCAP): Ononis Repens Whole administration will eventually change the levels of allergen-specific IgE and IgG4 in the blood, which is an intended effect of the therapy and not an 'interference' in the traditional sense.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.

• Severe, Uncontrolled Asthma: Patients with an FEV1 consistently below 70% of predicted or those with frequent acute exacerbations are at an unacceptably high risk of fatal anaphylaxis.
• Recent Myocardial Infarction or Unstable Angina: The physiological stress of a systemic reaction and the subsequent need for epinephrine could be fatal for these patients.
• Hypersensitivity to Excipients: Patients with a known severe allergy to glycerin, phenol (a common preservative), or the diluent used in the extract.
• Inability to Communicate: Patients who cannot report early symptoms of a reaction (e.g., very young children or those with severe cognitive impairment) may not be suitable candidates.

• Pregnancy (Initiation): Immunotherapy is generally not started during pregnancy due to the risk of anaphylaxis-induced fetal hypoxia. However, if a patient is already on a stable maintenance dose, it may be continued.
• Autoimmune Diseases: Patients with active systemic lupus erythematosus (SLE) or rheumatoid arthritis may have unpredictable immune responses to allergenic extracts.
• Malignancy: Patients undergoing active chemotherapy or those with certain immunodeficiencies.

Patients allergic to Ononis Repens Whole may show cross-sensitivity to other members of the Fabaceae (Leguminosae) family, such as clover, alfalfa, or even peanuts and soy. This must be considered when interpreting skin test results and managing the patient's overall allergy profile.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Ononis Repens Whole.

Ononis Repens Whole is classified as FDA Pregnancy Category C. This means that animal reproduction studies have not been conducted, and it is unknown whether it can cause fetal harm. The primary risk during pregnancy is not the extract itself, but the potential for a systemic reaction (anaphylaxis) in the mother. Anaphylaxis can lead to maternal hypotension and uterine contraction, resulting in fetal hypoxia (lack of oxygen) or miscarriage.

Clinical Practice Guideline: Healthcare providers generally do not initiate Ononis Repens Whole testing or immunotherapy during pregnancy. If a patient becomes pregnant while already on a stable maintenance dose that is well-tolerated, the physician may choose to continue the therapy at the same or a slightly reduced dose, as the risk of a reaction is lower during the maintenance phase.

It is not known whether the allergenic proteins in Ononis Repens Whole are excreted in human milk. However, since these are large proteins that are degraded locally and systemically, the risk to the nursing infant is considered negligible. The benefits of maternal allergy control usually outweigh the theoretical risks. No adverse effects in nursing infants have been documented in relation to allergenic extract use by the mother.

Ononis Repens Whole is used in children, particularly for managing allergic asthma and rhinitis. Studies have shown that allergen immunotherapy in children can prevent the development of new sensitivities and reduce the risk of progressing from rhinitis to asthma (the 'Allergic March').

• Age Limit: Rarely used in children under 5 years of age due to the difficulty of monitoring for reactions.
• Growth Effects: There is no evidence that allergenic extracts affect growth or development.

Elderly patients (over 65) require careful evaluation.

• Cardiovascular Risk: Older adults are more likely to have underlying heart disease, making them more vulnerable to the effects of anaphylaxis or the side effects of epinephrine.
• Medication Interactions: Higher likelihood of being on beta-blockers or ACE inhibitors.
• Skin Reactivity: Reduced skin mast cell density may lead to smaller wheal sizes during diagnostic testing.

There are no specific guidelines for Ononis Repens Whole in renal impairment. Since the product is biological and protein-based, renal clearance is not a primary pathway for the active allergens. However, patients with end-stage renal disease (ESRD) may have altered immune function, requiring a more cautious approach to dosing.

No dosage adjustments are required for patients with hepatic impairment. The liver is not involved in the primary processing of these allergenic extracts.

> Important: Special populations require individualized medical assessment.

Ononis Repens Whole functions as an immunomodulator. In the diagnostic phase, it acts as an antigen that binds to pre-sensitized IgE on mast cells. In the therapeutic phase, its molecular mechanism involves:

1. 1Desensitization: Early reduction in mast cell and basophil degranulation.
2. 2T-cell Shift: A shift from a Th2-dominated response (which produces IgE) to a Th1-dominated response (which produces IgG and Interferon-gamma).
3. 3Induction of T-regulatory (Treg) Cells: These cells produce IL-10, which suppresses allergic inflammation and induces B-cells to switch from IgE production to IgG4 production.

• Dose-Response: The skin wheal size is generally proportional to the concentration of the extract and the patient's level of IgE sensitization.
• Onset of Effect: Diagnostic results are visible within 15-20 minutes. The therapeutic effect of immunotherapy usually takes 6-12 months of consistent treatment to become clinically significant.
• Duration: The diagnostic effect lasts only a few hours. The therapeutic effect of a full course (3-5 years) of immunotherapy can last for several years after discontinuation.

| Parameter | Value |

|---|---|

| Bioavailability | N/A (Subcutaneous/Percutaneous) |

| Protein Binding | Minimal (Local interaction) |

| Half-life | Proteins: Minutes to Hours; Immunological Effect: Years |

| Tmax | 15-30 minutes (local reaction) |

| Metabolism | Proteolysis by local and systemic proteases |

| Excretion | Minimal renal/fecal excretion of intact proteins |

Ononis Repens Whole extract is a complex mixture of proteins, glycoproteins, and polysaccharides. The primary allergenic components are the proteins extracted from the plant tissue.

• Molecular Weight: Ranges from 10 kDa to over 70 kDa for various protein fractions.
• Solubility: Highly soluble in aqueous solutions and 50% glycerin/water mixtures.
• Composition: Contains phenol (0.4%) as a preservative and may contain sodium chloride for isotonicity.

Ononis Repens Whole is classified as a Non-Standardized Plant Allergenic Extract. It belongs to the broader therapeutic category of Allergen Immunotherapy Agents. It is related to other plant extracts like Ragweed, Timothy Grass, and Oak extracts.